A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas.

Trial Profile

A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2015

At a glance

  • Drugs Tandutinib (Primary) ; Bevacizumab
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Planned end date changed from 1 Jan 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top